• Publications
  • Influence
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
BackgroundClinicians are required to assimilate, critically evaluate, and extrapolate information to support appropriate use of biosimilars across indications.ObjectivesThe objective of this studyExpand
  • 37
  • 2
  • PDF
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite
BackgroundThis double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly®), anExpand
  • 28
  • 1
  • PDF